A detailed history of Promus Capital, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Promus Capital, LLC holds 221 shares of LLY stock, worth $225,795. This represents 0.11% of its overall portfolio holdings.

Number of Shares
221
Previous 221 -0.0%
Holding current value
$225,795
Previous $172 Million 2.12%
% of portfolio
0.11%
Previous 0.11%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 25, 2025

BUY
$713.71 - $898.95 $27,834 - $35,059
39 Added 21.43%
221 $172,000
Q2 2025

Aug 14, 2025

SELL
$713.71 - $898.95 $154,161 - $194,173
-216 Reduced 54.27%
182 $142 Million
Q1 2025

Aug 25, 2025

BUY
$725.72 - $929.72 $185,058 - $237,078
255 Added 140.11%
437 $361 Million
Q4 2024

Aug 25, 2025

BUY
$727.2 - $932.06 $185,436 - $237,675
255 Added 140.11%
437 $337 Million
Q4 2024

Feb 06, 2025

BUY
$727.2 - $932.06 $289,425 - $370,959
398 New
398 $307 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $971B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Promus Capital, LLC Portfolio

Follow Promus Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Promus Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Promus Capital, LLC with notifications on news.